GERN — Geron Corporation Stock Price, Chart & AI Report

Neutral Feb 25, 2026 • 12:00 UTC GlobeNewswire Inc. • Na

Geron Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Geron Corporation reported full year 2025 RYTELO net product revenue of $184 million with Q4 revenue of $48 million. The company ended 2025 with $401 million in cash and expects 2026 RYTELO revenue between $220-240 million. Operating expenses totaled $255 million in 2025, within guidance. Geron implemented a workforce reduction of approximately one-third in December 2025 and reiterated focus on driving U.S. commercial growth while pursuing international expansion opportunities.

GERN RYTELO imetelstat lower-risk myelodysplastic syndromes financial results product revenue commercial strategy workforce reduction

Sentiment note

Mixed signals: positive revenue growth ($184M in 2025 vs $76.5M in 2024) and strong cash position ($401M), but offset by net loss of $85.8M in 2025, significant workforce reduction (one-third of staff), and 2026 revenue guidance suggesting slower growth momentum. The company remains financially viable but faces execution risks in commercialization.

Neutral Dec 11, 2025 • 13:00 UTC GlobeNewswire Inc. • Harout Semerjian

Geron Corporation Announces Strategic Restructuring Plan to Position the Company for Long-Term Value Creation

Geron Corporation plans to reduce workforce by one-third and streamline operations to improve financial discipline, focusing on RYTELO commercial growth and clinical development while reducing 2026 operating expenses.

GERN restructuring workforce reduction operating expenses RYTELO blood cancer

Sentiment note

The company is proactively managing costs and maintaining strategic focus, but the workforce reduction suggests potential challenges in current business operations

Positive Dec 4, 2025 • 17:20 UTC Benzinga • Prnewswire

Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points

Multiple biotech companies are advancing innovative immunotherapy and targeted treatments for blood cancers, with significant clinical trial progress and FDA approvals in acute myeloid leukemia (AML) and related hematologic conditions.

GTBP GERN KURA SLS immunotherapy blood cancer AML clinical trials

Sentiment note

Achieved $47.2 million in product revenue, completed patient enrollment in Phase 3 trial, and strengthened leadership team

Negative Oct 23, 2025 • 22:14 UTC GlobeNewswire Inc. • Bragar Eagel & Squire, P.C.

GERON (GERN) INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Geron Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Law firm investigating potential claims against Geron Corporation regarding alleged misleading statements about drug Rytelo's launch and growth potential during February 2024-2025 period.

GERN investigation stockholders securities Rytelo fiduciary duties

Sentiment note

Potential breach of fiduciary duties alleged, with claims of minimizing risks and providing potentially misleading information about drug launch and commercial prospects

Neutral Oct 22, 2025 • 12:00 UTC GlobeNewswire Inc. • Cassava Sciences, Inc.

Cassava Sciences Appoints Dawn C. Bir to the Board of Directors

Biotechnology company Cassava Sciences announced the appointment of Dawn C. Bir to its Board of Directors, bringing extensive biopharmaceutical executive experience to support the company's clinical development of simufilam for TSC-related epilepsy.

SAVA GERN SLNO BIIB biotechnology board appointment simufilam TSC-related epilepsy

Sentiment note

Mentioned as a current board position for Dawn Bir

Positive Oct 13, 2025 • 20:34 UTC GlobeNewswire Inc. • Geron Corporation

Geron Corporation Announces Executive Leadership Transitions and Appointments

Geron Corporation has appointed four new executives, including Ahmed ElNawawi as Chief Commercial Officer, to lead commercial strategy and drive growth for its blood cancer treatment RYTELO®.

GERN executive appointments leadership transition RYTELO blood cancer commercial strategy

Sentiment note

The company is strengthening its leadership team with experienced executives, expanding commercial capabilities, and focusing on growth and potential portfolio expansion

Neutral Aug 19, 2025 • 12:00 UTC GlobeNewswire Inc. • Patrick Mooney

SpyGlass Pharma Appoints Elizabeth O’Farrell to its Board of Directors

SpyGlass Pharma announced the appointment of Elizabeth O'Farrell to its Board of Directors, bringing over 30 years of healthcare industry experience. She will serve as an Independent Director and Chair of the Audit Committee, supporting the company's advancement of its Drug Delivery Platform for glaucoma management.

LLY LNSR GERN GMAB glaucoma drug delivery ophthalmology clinical trials

Sentiment note

Briefly mentioned as another board position for O'Farrell with no substantive context

Negative Aug 13, 2025 • 23:52 UTC GlobeNewswire Inc. • Bragar Eagel & Squire, P.C.

GERON (GERN) ALERT: Bragar Eagel & Squire, P.C. is Investigating Geron Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Law firm investigating potential claims against Geron Corporation regarding alleged misrepresentations about drug Rytelo's launch and growth potential during February 2024-2025 period.

GERN shareholder investigation class action Rytelo imetelstat fiduciary duties

Sentiment note

Potential breach of fiduciary duties alleged, with claims of minimizing risks and providing potentially misleading information about drug launch and commercial potential

Negative May 12, 2025 • 13:54 UTC Benzinga • Prnewswire

GERN Investors are Reminded of an Opportunity to Lead Geron Corporation Securities Fraud Lawsuit with the Schall Law Firm

Geron Corporation (GERN) is facing a securities fraud lawsuit for allegedly making false and misleading statements about its drug Rytelo's launch and potential growth, leading to investor losses.

GERN Geron Corporation securities fraud lawsuit

Sentiment note

The article states that Geron Corporation is facing a securities fraud lawsuit for allegedly making false and misleading statements about its drug Rytelo, which led to investor losses.

Negative May 11, 2025 • 12:17 UTC GlobeNewswire Inc. • N/A

Faruqi & Faruqi Reminds Geron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 12, 2025 - GERN

Faruqi & Faruqi, LLP is investigating potential claims against Geron Corporation (GERN) for making false and/or misleading statements about its drug Rytelo. The company's stock price declined significantly after it announced that Rytelo's growth had flattened due to seasonality, competition, lack of awareness, and the burden of the monitoring requirement.

GERN Geron Rytelo class action lawsuit

Sentiment note

The article indicates that Geron made false and/or misleading statements about its drug Rytelo, leading to a significant decline in the company's stock price. This suggests a negative sentiment towards the company.

Neutral May 9, 2025 • 13:00 UTC GlobeNewswire Inc. • Pomerantz Llp

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 3D Systems Corporation - DDD

3D Systems Corporation reported weak financial results for Q4 2024, missing consensus estimates for sales, operating income, and earnings. This led to a 20.96% drop in the company's stock price.

DDD HUM GERN 3D Systems Corporation Humana Inc. Geron Corporation

Sentiment note

The article mentions a class action lawsuit filed against Geron Corporation, but does not provide any details on the company's performance or the nature of the lawsuit.

Negative May 9, 2025 • 12:00 UTC GlobeNewswire Inc. • N/A

INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Geron Corporation and Certain Officers – GERN

Geron Corporation, a biopharmaceutical company, is facing a class action lawsuit over alleged violations of federal securities laws related to the launch and commercialization of its drug RYTELO for the treatment of lower-risk myelodysplastic syndromes.

GERN Geron Corporation RYTELO myelodysplastic syndromes securities fraud

Sentiment note

The article alleges that Geron made materially false and misleading statements about the launch and commercialization of RYTELO, which led to the stock price dropping significantly when the company reported disappointing Q4 2024 results.